Skip to main content
. 2015 May 12;6(24):20474–20484. doi: 10.18632/oncotarget.4105

Figure 6. A diagram describes the mechanisms by which catalytic Topo II inhibitors and anti-AR agents block AR pathway in prostate cancer cells.

Figure 6